An interventional study of VisuALL and Humphrey Visual Field in Visual Field Defect, Peripheral, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 4 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Duke University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Glaucoma by Duke University — 5 open to participants now, 5 under way, none of them phase 3. Glaucoma · Duke University.
Among the 15 studies in Glaucoma by Duke University, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, and was the 9th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →5 of the 15 studies in Glaucoma by Duke University are open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 1 mo+ · Healthy volunteers
Duke University · Sites in United States
Ages 18+
Duke University · Sites in United States
Healthy volunteers
By country, each count listing its studies:
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 4 Years to 21 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 76 across the 13 interventional studies, 591 across the 2 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
3 of the studies in Glaucoma by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07298356Duke UniversityAutomated Applanation Tonometry - Updated | 2026-12-29 |
| NCT06841575Duke UniversityAdvancing Pediatric Retinal Imaging With Auto-aligned OCT | 2027-03 |
| NCT06139523Duke UniversityOptimize Pediatric OCT Imaging | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Glaucoma by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test a new way of measuring the peripheral vision (called a visual field test) using a device which can be worn as goggles rather than being a large instrument the patient must sit at. This new visual field test (called VisuALL) is an FDA-approved virtual reality system which has been used in adults and children. This study will compare the performance of the VisuALL to the standard testing for peripheral vision, which is called the Humphrey Visual Field (HVF) test.
The study will recruit both healthy children, as well children and young adults who have eye conditions which require visual field testing as part of their standard care. The test will be performed on a day when the child or young adult already has a scheduled eye appointment as standard care. The test does not touch the eyes or require any eye drops to be given, and there is no known risk associated with the test itself. There may be a risk of loss of confidentiality. Participating in this study will require approximately 30 minutes, has no extra cost associated with it, and will be compensated by a parking pass for the day of the visit. There are no direct benefits for participants.
Selected participants will be also be given training and then loaned a home VisuALL system to allow home visual field testing. If your child is selected, additional information would be provided.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will perform both the standard of care Humphrey Visual Field (HVF) and the VisuALL Virtual Reality Visual Field.
Device: VisuALL · Device: Humphrey Visual Field
This group will only perform the VisuALL Virtual Reality Visual Field.
Device: VisuALL
Virtual Reality Visual Field Device
Standard of care Visual Field test
Mean deviation results of visual field parameters
Mean deviation of the visual field is one score measured in decibels calculated from device reading
Time frame: During office visit, approximately 30 minutes
Pattern standard deviation results of visual field parameters
Pattern standard deviation of the visual field is one score calculated from device reading
Time frame: During office visit, approximately 30 minutes
Sensitivity results of visual field parameters
Sensitivities are the results of each space in the visual field measured in decibels
Time frame: During office visit, approximately 30 minutes
Percent of times that scotomas were visualized as measured by visual field tests
Time frame: During office visit, approximately 30 minutes
Percent of participants stating satisfaction as measured by questionnaire
12 questions with strongly disagree to strongly agree
Time frame: During office visit, approximately 5 minutes
Percent of patients able to use VisuALL in-office testing as measured by patient observation
Time frame: During office visit, approximately 30 minutes
Percent of patients able to use VisuALL home testing as measured by device reading
Home testing will be done in a few patients that demonstrate facility with the device
Time frame: During office visit, 30 minutes
Plan to share: No
Started Jan 2022 (actual). Primary completion is estimated for Jun 2028, 76 months after the start.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 76 months is above that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.